+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behavior of polymer matrix and oros dosage forms of oxprenolol in healthy volunteers



A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behavior of polymer matrix and oros dosage forms of oxprenolol in healthy volunteers



British Journal of Clinical Pharmacology 19(Suppl. 2): 177S-184S



A new osmotic drug delivery system (Oros) was evaluated in multiple-dose studies in young healthy volunteers as a sustained-release vehicle for once-daily administration of oxprenolol. Two Oros systems were examined in 2 separate studies, one containing 170 mg oxprenolol succinate with an initial zero-order release rate of 10 mg/h, and the other containing 260 mg oxprenolol succinate with an initial release rate of 16 mg/h. These were compared respectively with conventional oxprenolol hydrochloride (Trasicor) 80 mg twice daily and polymer-matrix oxprenolol hydrochloride (Slow Trasicor) 160 mg once daily. Variations in mean plasma levels and .beta.-adrenoceptor blockade (measured by inhibition of exercise tachycardia) were considerably reduced on the 10/170 Oros once-daily compared with the Trasicor 80 mg twice-daily regimen. With both formulations there was no significant change in mean plasma concentrations or areas under the curve after 8 days' treatment, and similar pre-dose plasma concentrations were obtained. There was significant inhibition of exercise tachycardia throughout 24 h after the 10/170 Oros on the 8th day. The 16/260 Oros system gave smoother pharmacokinetic and pharmacodynamic profiles, and on repeated dosing a higher mean pre-dose plasma oxprenolol concentration than Slow Trasicor. Drug availability was similar for the 2-dose forms, suggesting an acceptable level of absorption of oxprenolol from most of the gastrointestinal tract. On the 8th day, exercise heart rate was significantly reduced throughout 24 h with 16/260 oxprenolol Oros, but only between 1 and 15 h with Slow Trasicor.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 004590589

Download citation: RISBibTeXText

PMID: 4005120


Related references

Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers. British Journal of Clinical Pharmacology 19(Suppl. 2): 171s-175s, 1985

A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers. British Journal of Clinical Pharmacology 19(Suppl. 2): 239s-244s, 1985

Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form. British Journal of Clinical Pharmacology 19(Suppl. 2): 185s-190s, 1985

Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. British Journal of Clinical Pharmacology 19(Suppl. 2): 163s-169s, 1985

Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. Clinical Therapeutics 38(2): 348-357, 2016

Multiple oral dose pharmacokinetic and pharmacodynamic study of a sustained-release formulation of bunazosin (E1015) in healthy volunteers. Drug Investigation 5(6): 302-308, 1993

Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Revista Espanola de Quimioterapia 20(1): 51-60, 2007

Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittel-Forschung 60(8): 483-491, 2010

Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. Bmc Pharmacology and Toxicology 15: 75, 2016

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility 72(6): 1006-1012, 1999

Pharmacokinetic profile of two different pharmaceutical forms of theophylline (a slow release tablet and a syrup) after multiple dose administration to healthy human volunteers. Memorias do Instituto Oswaldo Cruz 88(1): 155-158, 1993

Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. British Journal of Clinical Pharmacology 48(3): 453-456, Sept, 1999

Safety, Tolerability, And Pharmacokinetic And Pharmacodynamic Effects Of Pf-06751979, A Potent And Selective Oral Bace1 Inhibitor: Results From Phase1 Single And Multiple Ascending Dose Studies In Healthy Young And Older Volunteers. Alzheimer's & Dementia 13(7): P575-P576, 2017

Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneimittel-Forschung 52(4): 233-242, 2002

Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers. Clinical Pharmacology and Therapeutics 102(1): 115-122, 2016